Full Prescribing Information
 
Important Safety Information
hamburger menu close icon hamburger menu close icon

Eligible patients may be able to get Wynzora for as little as

$35*

Get details

*See rebate card for details.

$

Psoriasis cream built to deliver

Efficacy | Safety | Convenience… by design1,2

Wynzora is the first and only water-based calcipotriene and betamethasone dipropionate cream for the treatment of plaque psoriasis1-3

EPI Health is committed to helping patients access Wynzora

Get details

*See rebate card for details

Wynzora Product and Rebate. Patients may be able to get Wynzora for as little as $35*

*See rebate card for details

Wynzora is powered by PAD™ Technology

See what makes Wynzora special

See what makes Wynzora special

Explore the MOA
https://www.wynzora.com/wp-content/uploads/2021/08/pad-card-mobile-cropped.png

Results you can see

Explore before and after photos from the clinical trials

Explore before and after photos from the clinical trials

See the results
weekly progressions of knees using Wynzora
left control right control

Eligible patients may be able to get Wynzora for as little as

$35*

Get details

*See rebate card for details.

Wynzora was assessed in the following categories:

Efficacy

Your patients may be able to achieve greater plaque clearance with this unique water-based topical cream.1,3,4

See efficacy data

Safety

Your patients deserve a treatment that works well and is safe to use— especially when it comes to application-site irritation.1,4

View safety

Convenience

Patients reported that Wynzora was less disruptive to their daily routine than the calcipotriene and betamethasone dipropionate topical suspension.2,4

Explore convenience data

EPI Health is committed to helping patients access Wynzora

Eligible patients can get Wynzora for as little as $35 per fill*

Get details

*At participating pharmacies. Limitations apply. Reduced copay for commercially insured eligible patients. Uninsured and government-insured patients are not eligible for these offers. See rebate card for details.

arrow

Indication and Use

Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.

Important Safety Information

  • Wynzora Cream is for topical use only.
  • Patients should not use more than 100g of Wynzora Cream per week.
  • Wynzora Cream should not be used near or in the mouth, eyes, or intravaginally.
  • Patients should avoid using Wynzora Cream on the face, groin, or armpits, or if they have atrophy at the treatment site.
  • Patients should apply Wynzora Cream to the affected areas of the skin once a day for up to 8 weeks.
  • Patients should discontinue use once the plaque psoriasis is under control.
  • Patients should not use with occlusive dressings.
  • Hypercalcemia and hypercalciuria have been observed with use of topical calcipotriene.
  • Wynzora Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment.
  • Wynzora Cream may cause vision problems, including increasing the risk of cataracts and glaucoma.
  • It is not known whether Wynzora Cream may harm your unborn baby.
  • Breastfeeding women should not apply Wynzora Cream directly to the nipple and areola.
  • It is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Wynzora® Cream [package insert]. MC2 Therapeutics; 2020. 2. Præstegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62.3. US Department of Health and Human Services. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 41st ed. US Government Publishing Office; 2021. https://www.fda.gov/media/71474/download. Accessed June 24, 2021. 4. Data on file. MC2 Therapeutics.